Interview: Roberto Bellini, President & CEO, Bellus Health, Canada
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
Bellus Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company’s product pipeline and development strategy includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.
The Company’s lead program is KIACTA, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA is partnered with global private equity firm Auven Therapeutics. AA amyloidosis affects approximately 35,000 to 50,000 individuals in the United States, Europe and Japan.
Bellus Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
275 Armand-Frappier Blvd.
Laval,
Quebec
Canada
H7V 4A7
Tel.: (450) 680-4500
Fax: (450) 680-4501
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
Introducing Vantage BioTrials, a CRO focused on operational excellence with a lean and holistic approach to each project, Vatché Bartekian, president and co-founder, also advocates for greater visibility for Canada…
Allan O’Dette has been at the helm of the Ontario Investment Office since April 2017. As CIO, he underlines the importance of the life sciences sector in the province, while…
Speaking about the transformation from a pure service provider to true partner, Charles Grubsztajn of Neopharm Labs in Canada highlights the importance of thinking for clients rather than just with…
Whitney Green candidly describes what first surprised him as an American coming to Canada to head up operations as president and general manager of Roche Diagnostics Canada. He highlights the…
Mark Smithyes, president of Labtician Théa, highlights the company’s ambition to become the leader and preferred partner to optometrists and ophthalmologists in Canada by launching products from Laboratoires Théa’s innovative…
Montréal International, the strategic partner for foreign investment, international organizations, and talent, has served the city and surrounding areas for 22 years. Hubert Bolduc, president and CEO, and Christelle Fasano,…
Nadurel Pharma, headquartered in the technopole of Saint–Hyacinthe, Quebec, promotes natural health products complete with concrete clinical trial evidence. Martin Dufour, President and CEO, has been at the helm since…
Jaiveer Singh, CEO of Mint Pharmaceuticals explains the company’s business model and how it fits the characteristics of the Canadian market on the tenth anniversary of the company. He further…
Janet McDougall, president and founder of McDougall Scientific and John Amrhein, vice president in charge of business development, discuss the challenges that SME CROs are facing in Canada today, competing…
Tarik Henein, president of Generic Medical Partners, explains the company’s commitment to improving the lives of Canadians by connecting global generic development and manufacturing companies with the Canadian market. He…
Sylvie Bertrand, general manager of BSN medical Canada, an Essity company, highlights the value proposition BSN medical’s products bring to Canadian patients in chronic venous insufficiency, diabetic foot ulcers and…
Jean-Philippe Gentès, President, and CEO of the rapidly growing ready-to-use injectable manufacturer Sterinova, shares his ideas on the ‘Made in Canada’ label, innovation in North America and the pros and…
See our Cookie Privacy Policy Here